Wilmington – November 02, 2026 -- Chemours (NYSE: CC) reported third-quarter 2026 Adjusted EBITDA of $200 million, up from $189 million a year earlier, as TiO2 price increases and growth in high-value materials for data center and semiconductor customers offset a sharp decline in refrigerants.
Net Sales rose approximately 3% to $1.5 billion. Pricing added 5%, volumes subtracted 2%, and currency was a slight headwind. Net Income attributable to Chemours reached $196 million, or $1.29 per diluted share, versus $46 million, or $0.31 per share, a year earlier. The figure includes $150 million in PFAS insurance proceeds tied to the New Jersey judicial consent order, booked as a reduction to SG&A. Adjusted Net Income rose 19% to $31 million, or $0.21 per share.
Titanium Technologies lifts EBITDA to $85 million from $25 million
TT Net Sales climbed 11% to $680 million on a 10% global price increase and 1% volume growth. Prices rose in all regions. Volume gains in North America, Latin America and APAC excluding China outweighed declines in EMEA and China. Adjusted EBITDA Margin widened nine points to 13%. Sequentially, TT sales rose 3% on a 4% price gain.
Advanced Performance Materials grows EBITDA 71% as Performance Solutions sales jump 26%
APM Net Sales rose 8% to $337 million, with price up 6% and volume up 2%. Performance Solutions sales grew 26% year over year and 8% sequentially, driven by order book strength in data center and semiconductor end markets. Adjusted EBITDA increased to $24 million and margin rose two points to 7%.
Thermal & Specialized Solutions Adjusted EBITDA falls 30% to $136 million
TSS Net Sales dropped 9% to $510 million on a 9% volume decline. The prior-year quarter had benefited from the initial aftermarket channel fill linked to the stationary AC technology transition under the U.S. AIM Act. TSS Adjusted EBITDA Margin fell eight points to 27%. Sequentially, TSS sales declined 14% on seasonal North American demand.
CEO Denise Dignam said the company continues to navigate TSS stationary aftermarket dynamics and a softer macroeconomic environment.
Chemours settles with North Carolina and closes Kuan Yin sale at about $340 million
The company settled with the State of North Carolina and 11 local entities over PFAS and other historical discharges from Fayetteville Works, as well as PFAS contamination claims unrelated to that site, including from AFFF use. It also completed the Kuan Yin property sale for total net consideration of about $340 million, including $56 million in gross proceeds for the remaining land parcel. Chemours formally launched its Faizeon liquid cooling portfolio, comprising four two-phase direct-to-chip fluids and one immersion cooling fluid.
Net leverage stands at 4.3x with $1.7 billion in liquidity
Gross debt was $3.9 billion at September 30. Net of $698 million in unrestricted cash, debt was $3.2 billion. Liquidity totaled $1.7 billion, including $953 million of revolver capacity. Operating cash flow was $149 million versus $146 million a year earlier. It includes the $150 million insurance receipt, offset by roughly $100 million in restricted cash used for 2025 New Jersey settlement payments and about $25 million in Kuan Yin-related taxes. Capital expenditures rose to $51 million from $41 million, and Free Cash Flow slipped to $98 million from $105 million.
Fourth-quarter guidance calls for Adjusted EBITDA of $160 million to $185 million
Chemours expects consolidated Net Sales to fall 5% to 10% sequentially on seasonality in TSS and TT. Corporate Expenses are projected at $40 million to $45 million. Capital expenditures are guided to $75 million to $85 million, with positive Free Cash Flow.